All for being here with us at the Jefferies London Global Healthcare Conference. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. We are really pleased to have with us today the management team of Viridian Therapeutics. So we have Steve Mahoney, CEO, Shan Wu, CBO. Can I just ask you guys to briefly introduce the company? Then we got a lot of interesting stuff to get into.
Yeah, sure. Thanks everyone for coming today. Yes, we have a lot going on at the company, so I will try to do the overview very quickly so we can get to the questions. We just recently launched our first product, LUMVOA. We reported our first quarter numbers, which were very good, very exciting in terms of the execution. We did $24.7 million in revenue for the first quarter. We had over 100 patients on drug as of the September 30th date. So really encouraging. We are really excited about the start that we got. I am sure we will get into more details as well, so on this. Off to a great start. It is early, it is a first quarter of launch, but a lot of good signs. We also have our next-generation product that is coming in behind it.
We have our BLA that we will submit for the subQ version for IGF-1R, which we had two positive phase III readouts earlier this year. So really exciting to be able to put IGF-1R inhibition into an autoinjector pen for really easy self at-home administration. So we are looking forward to that BLA, Q1 2027, we are filing. We also have our TSHR program, which fits into our thyroid autoimmunity franchise with respect to a TSHR program that is going into the clinic starting this year, is our expectation. So we are moving forward there as well. That is an exciting program, big opportunity in the Graves population. Also has applicability possibly in TED, although IGF-1R sets the bar pretty high there. We are looking forward to that. We think that is a complementary program for our franchise. We also just recently put out data for our FcRn franchise.
We had two FcRn assets, VRDN-006 and VRDN-008. VRDN-006 was the Fc fragment, very much like the VYVGART asset. Then we had our VRDN-008 program, which is half-life extended. So what we recently just put out was potentially best-in-class FcRn profile, because we can get every eight-week dosing. We saw 74% peak IgG reduction. We saw sustained IgG suppression. We saw sustained IgG suppression out to eight weeks, which is a game-changer for patients. Obviously, albumin sparing, you needed to see that as well. So we are really happy with the thyroid eye disease franchise, the Graves program that is advancing, and then obviously FcRn to potentially have the best profile in FcRn would be really exciting.
Got it. Awesome. Thank you for the intro. You guys have a lot going on right now, so there is a lot to cover. Let us start with the LUMVOA launch. As I think high level about the TED market, TEPEZZA is doing what looks to be a pretty sustainable $2 billion per year revenue run rate. You guys, in my opinion, just simply have a better product. It is at least as good on efficacy, roughly comparable in safety, and much easier to give. In theory, if you just kind of take a step back and before you even do any doc calls, before you even do any surveys, you should take over TEPEZZA, is what I think. How fast should that happen?
Yeah, obviously timelines on that, we do think it is going to get fast to peak. We do think the market is conducive to that. It is a new start market. We do not switch patients off of the current other available product, TEPEZZA. So it does lend itself to a fast to peak. What fast to peak means in reality needs to be seen. Again, we are very happy with the first quarter of launch. I think that was a function of the product profile, to your point. I think given the fact that we had Breakthrough Therapy Designation, we had Priority Review designation for that drug, our application for that was on the basis of the rapid onset of treatment effect. So we were seeing people, a majority of people were getting proptosis response after just one infusion, and that had not been seen before.
We also saw incredible diplopia benefit in the chronic patient population of thyroid eye disease. This is people that were not only responding on the Gorman score, but they are actually achieving complete resolution at a rate that we had not seen before either. Our drug was designed to be a full antagonist. TEPEZZA is a partial antagonist. So we designed it that way so we could dose less in terms of the volume that we are dosing, but also the number of infusions, which ultimately comes into the fact that we are dosing for a five-infusion course versus the eight-infusion course for TEPEZZA. Those three elements, rapid onset of treatment, the diplopia, and the shorter course of treatment are all really good benefits of the profile that have lent itself to what we have seen so far, but it is still early.
Got it. Yeah. And sorry, Steve, I know I asked you the leading question to lead all leading questions. But in terms of the metrics that you guys disclosed, so you disclosed the $24.7 million in your first full quarter, which is an awesome result. You gave us the metric that you have more than 100 patients on therapy, so that basically tells us that we know this is not stocking, this is actually infusions. But you did not give us as much in the sense of leading indicators, like prescriptions or things like that. How should we think about the trajectory and kind of the pace of growth over the next few quarters?
Yeah. Well, maybe I will start, and Shan can jump in. I think the most concrete metrics that you are going to get is to answering the question as to whether the first three months of your launch are going well is your revenues and whether you are getting patients on drug. So, those are the numbers that we provided. So we think those are the most concrete measurements that tell you whether we are doing well on the execution side. We do say that it is still early, that we have more work to do. When we start on day one of launch, you do not have any policy coverage, so you have to work through the payers in order to advance that and to get even more patients on therapy.
I think right now we are telling people that we feel really good about how things are going on the execution side, our field engagement, our market access, and then ultimately demand. So I think we answered those three questions.
Got it. Then in terms of, like, you are characterizing, you said many times that you are very pleased with the progress. If we were to just kind of find Steve from six months ago and ask him, blast from the past, would you say the launch so far has gone better than what you would have hoped six months ago? Like, are you tracking ahead of what you wanted to deliver on?
Yeah. I mean, I think we have been clear that it certainly exceeded our expectations, but then when I do look back, so thank you for that, formal question. When we do look back, I think it is pretty obvious as to why we executed so well. We hired our sales team early. Although they could not be in the field talking about the product, they could go out and profile accounts and make relationships so that they were able to hit the ground running on day one of launch. We also took advantage of the preapproval information exchange capability that you have when you can go out and show your profile to payers. Payers are familiar with IGF-1R as a mechanism. They are familiar with TEPEZZA. They are familiar with our data because we had done quite a bit of payer research prior to that.
The nice part there was that they indicated to us that if we provided parity pricing, that they would provide parity coverage. TEPEZZA had done a lot of legwork over the years. It took them close to five years to get to 85% of covered lives, which is a great footprint for us to step into. We are not there yet on coverage because even when you get approved, you still have to work through each payer's timelines, with P&T committees and things like that. Still more work to do there. I think we indicated on the call that we had achieved about 30% covered lives by the end of September.
When we look back, that legwork, hiring the team early, getting in front of payers early, we had a lot of high TEPEZZA prescribers that were PIs in our trial, so our clinical trial infrastructure was helpful in terms of familiarity with the drug. I think all those things helped.
In terms of execution as well, I also add that the commercial strategy here is a simple one. We are not trying to reinvent the wheel. There are about 2,000 prescribers who write more than 80% of IGF-1R scripts, and so that is our focus for the LUMVOA IV launch. Even in August with Q2 earnings, a month in, so just four weeks, we talked about having already engaged with over 95% of those core prescribers. We were able to get out the door with our field force within 24 hours. Within launch, our field was talking about LUMVOA with these physicians. A lot of that comes from the preapproval groundwork that we laid with both the field as well as with market access.
That has led to the ability to talk very simply about the profile, and on the execution side, being able to pull through and generate quite a bit of enthusiasm with these physicians, which goes again to Steve's earlier point about, we do think that we can get to a very healthy peak market share and get there quickly because of the familiarity with IGF-1Rs with this group of core prescribers, as well as our ability to engage with them.
My final point is, it always helps to have a great team.
Yeah.
We have a great team.
Yeah. Just conceptually, Steve and Shan, should we think about this as one of those situations where you have an incumbent product that's kind of been on the market for five plus years, has gotten a little bit stale, and that by making this launch the core focus of a lot of your effort and what you're doing, you're able to basically out-innovate and outmaneuver and out-execute kind of an incumbent here? Is that how we should conceptually think about it? Is that how you feel about it?
Well, I think that physicians and patients welcome having options when it comes to their treatment. We're very happy to be able to deliver that. I think that we did design elegrobart a specific way to make sure that we could try to introduce an option that would appeal to patients, both with respect to the things that we talked about, with respect to how quickly they were seeing response, what was their course of treatment, how could we design the molecule in a way to be able to achieve that. So yeah, we feel good about where we are. We still have more work to do.
Got it. I have, I think, one last one on LUMVOA. You mentioned access. You mentioned that you're currently at 30%, like, formal policy. Others are getting covered via medical exception. As we get into next year, you'll also have the permanent J-code in place as of January 1 as well. How should we think about the extent to which kind of broadening or easier access helps the launch?
Yeah, I wouldn't put too much stock in the J-code. We haven't seen it with a big impact on us. Now, in a buy-and-bill setting, with regional or national infusion center networks, they're used to dealing with temporary J-codes versus permanent J-codes. We do anticipate that when we get our and we did get assigned a J-code. It'll go in effect in January 1. That might help with some of the smaller infusion centers, but I think from an overall impact, we can easily manage that for infusion centers that have concerns about payment terms. We can do temporary fixes there to alleviate that. It hasn't had a huge impact on us yet, and I would expect that to still be the case once we turn the corner into January.
Got it. Okay.
On the payer coverage side, just to touch on that point as well. So, 30% cover lives at the end of September, at the end of the first quarter after launch. That doesn't mean that the other 70% of patients, it's important to know that those patients don't have access to LUMVOA. Actually, they do, and they go through a medical exception process. It's a high-priced biologic. TEPEZZA is also a high-priced biologic. There is a time that it takes to get through prior authorizations. TEPEZZA is about 60 to 90 days after six years from launch. That would be a reasonable place to land from a steady state standpoint. We're probably on the upper end of that because most patients are still going through the medical exception process to get to prior auth.
But we hope to bring those numbers down as our policy coverage continues to increase, and we are well on our way and on track to that, getting to critical mass within a six to nine-month period since launch.
Got it. Okay. I want to make sure we have time to touch on subQ elegrobart and then FcRn as well. Just high level on subQ, can you talk about the potential that you see there and whether you see this more as kind of part of a TEPEZZA displacement or more of an opportunity to expand this market?
Well, I think we certainly expect expansion. I think the ease of the profile of a subQ autoinjector mailed to people's homes where they can self-administer in a matter of seconds. We are advancing both Q4 weekly and Q8 weekly. That is our plan as we go to FDA. Q8 weekly is three administrations and you are done at day one, week eight, week 16, and you are done. So, the convenience of that will certainly be helpful to people. Remember, this is IGF-1R in a pen, and we think that is going to be really helpful for across the moderate to severe patient population, which includes active and chronic patients. So, we fully expect, and what we look forward to is having the IV offering, which we think will stick around, because there will be patients that need to be in a controlled setting.
There are physicians who are going to want patients in a controlled setting. And on the very severe end of that spectrum, where it can be sight-threatening, you are going to want that IV option still available. So, we have always said that. We still feel very confident in that. We think IV will grow with that expanded market, but we do think the bulk of the expansion will be driven by subQ. It will simply bring people off the sidelines, patients who have said, "You know what? I cannot really make an infusion work in my lifestyle." Remember, this is primarily women in their 40s and 50s, so they have got jobs, they have got families, active lives. Not always easy to do infusions. So, we think there are patients out there who could get pulled in by virtue of having the subQ available to them.
Got it. When you had the initial subQ data, you made this comment that you were capturing most of the efficacy of the IV options that are available. As you think about what it takes to expand this market, it sounds like you really think having that more convenient option is a big enabler. Is that what you are getting at?
Well, I think our market research shows that a lot of the physicians that we talk to recognize that this is IGF-1R, and there is some variability in some of these clinical trials. But market research strongly suggests that physicians say, "Okay, I see that. That is IGF-1R, and it is in a pen." We do think that the efficacy is there, the safety profile is there, and we expect it to work across that spectrum. Because if you have IV and then you have Q4W, where the data was very clear that we were seeing the diplopia response and resolution in that Q4W arm, that was really important to see, and possibly as an alternative to IV.
Then you have the Q8W arm, where if diplopia is not your primary complaint, but your proptosis is still a problem and bothersome, there is a lot of pain associated with this disease. People often forget that. That does not get talked about enough. We think that the Q8W option could be a great option for those types of patients as well. So, we like having offerings across the spectrum.
Yeah. Steve, what I am getting at is, I am just curious if you agree. The read that I have on this is that the relatively subtle differences in efficacy between subQ and IV, I personally think, is something that investors are picking at a lot more than physicians and patients would, and that your subQ, I personally think, would be quite successful. Is that a fair read on it?
Yeah, I think that's fair with respect to the physicians that we're talking to understanding what that profile is. They know and realize that IGF-1R is the foundational approach to thyroid eye disease. When they see that IGF-1R in a pen, then that's encouraging to them with respect to their patients.
Got it. I like the IGF-1R in a pen. I feel like that's a good sales message for you guys.
Thanks.
I want to get into FcRn. You guys had some pretty exciting data last week. I just want to get to the core of the debate. I think a lot of investors have seen the data, understand the profile that you're trying to bring. The big question that people have is how to think about an on-body system that could be out to every eight weeks compared to a market that will likely have once-weekly high-volume autoinjector, and which may have some sort of a monthly option. It might be one pen, it might be two pens. We'll see what that looks like. That's kind of what you're going to be competing with from an administration perspective. How do you think about that?
Yeah, it's a great question. A lot wrapped in there, so maybe take a little bit of time also to-
I see you have the device, so a little show and tell.
Yeah, a little show and tell. This is the device that we licensed from Enable Injections. It is a device that is the only one that is available on the market, commercially validated as well, that can provide subcutaneous at-home administration of a volume level and dose level that we need for FcRn. Maybe just for those who are catching up on the FcRn story, the profile we shared last week, hard to believe that was just a week ago, we think is potential best in class. Looking at VRDN-008, which is a half-life extended FcRn, hard to engineer, took us a while. We worked with Paragon Therapeutics and licenses from Paragon Therapeutics, and have been working to get it through healthy volunteers to really confirm the half-life extension profile.
What we saw was 15 to 18 days of half-life, and that is phenomenal, really unprecedented with regards to FcRn. You compare that to VYVGART, which is three to five days, and the full-length antibodies like IMVT-1402, Immunovant IMVT-1402, as well as IMAAVY. IMAAVY has a 29-hour half-life. These are, to be able to get to 15 to 18 days is a phenomenal achievement for FcRn in general, and that is what allows us to not only achieve deep, but also a sustained reduction of IgG. The observed data from phase I, being able to see those IgG levels maintained out to 12 weeks, which was eight weeks beyond the last dose.
Not to make cross-trial comparisons, it is a good reminder that the clinical experience with VYVGART has IgG reductions of 61% to 67%, and those levels have translated very well to clinical efficacy in a number of indications, including MG, where we have the biggest body of evidence of IgG reductions translating to clinical efficacy. With the 74 peak and sustained IgG reductions that we see every eight weeks, supported by modeling data as well, we feel very good about our ability to at least match VYVGART in efficacy. Remember that this is the device I was showing before, very small, simple, at-home self-administration that patients can do. It is a truly phenomenal patient experience, positive patient experience. We have exclusive access, global rights to the device through Enable Injections for FcRn-targeted therapies.
From a competitive landscape standpoint, being able to offer this every eight weeks, it means only seven administrations over the course of an entire year for FcRn therapies. That's a phenomenal, transformative potential therapy for patients. We think this is potential best in class. As we said last week, we plan to start at least one registrational trial in 2027, starting with myasthenia gravis, which is a large market on track to generate close to, if not over, $7 billion in revenues this year for FcRn's alone, and still projected to continue to grow as well in the coming years. To have a potential best-in-class Q8 week VRDN-008, we think makes a lot of sense for really bringing the best patient experience to these patients who are relying on FcRn treatments to improve their disease.
Got it. That's super helpful perspective, and I think a lot of investors do appreciate the kind of profile that you're bringing. One question that I have here is, given how competitive this can be, like moving this market that's stuck at once weekly into a potential every eight-week type of administration, why not go broad? I mean, this kind of space is changing so rapidly. The opportunity for FcRn's, once all is said and done, is likely to be just ginormous, to kind of say it simply. Why start in one spot instead of going everywhere where we've seen de-risking for FcRn's?
Yeah. It's a good leading question as well. Our plan is to go broad with this potential profile because we think of it as potential best in class. There are a number of validated indications. That's a really good setup for us. I think also as the field of FcRn continues to mature, as others ahead of us are generating clinical evidence and clinical data and further de-risking additional indications, that provides us with additional opportunities as well to take, again, this potential best-in-class profile into additional indications.
Got it. Great. So maybe just to wrap up, Steve, would love any kind of closing remarks that you could sort of provide. Specifically, I want to understand, like across multiple things happening for you over the next 12 to 24 months, you have the continuing launch of LUMVOA, you have progress towards approval for subQ elegrobart , you have both FcRn and TSHR kind of coming to bear as well. What do you think is the most underappreciated part of the story right now for investors?
Well, obviously, we are very excited about LUMVOA start. We are very excited about the prospects for Ele subQ. We do think TSHR is a potentially big opportunity, not only in Graves, but also could have applicability in TED. Again, complementary to our portfolio, a lot of overlap with our team structure, our call points. So the synergies there are really important for people to understand. Then FcRn, I think people need to probably get more familiar with our story on FcRn, because we really do think this is potentially best in class, given the profile and the direction that we are heading in.
Got it. Yeah. I mean, for what it is worth, I agree on that point. I mean, the other FcRn pure play company, I think, is a $6 billion company. So I think there is a lot of room for you guys to run on that.
Right. We get to pay attention to the landscape and see what makes most sense for capital allocation too, which is an important point.
Got it. Awesome. Well, thank you so much, Steve and Shan, for being with us here today. Thank you to all the investors who joined us in the room and online as well.
Yeah. Thanks, Faisal.